Results 71 to 80 of about 1,652 (181)

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Food Science &Nutrition, Volume 13, Issue 2, February 2025.
Illustrating the mechanism of Proteolysis Targeting Chimeras (PROTACs), development of ligands available for PROTACs, PROTACs targeting cancers, and its advantages. PROTACs offer a versatile strategy for personalized cancer treatment ABSTRACT Proteolysis Targeting Chimeras (PROTACs) have revolutionized cancer therapy by offering a selective and ...
Saooda Ibrahim, Muhammad Umer Khan, Iqra Khurram, Raima Rehman, Abdur Rauf, Zubair Ahmad, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Mohammed Mansour Quradha   +8 more
wiley   +1 more source

Data from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

, 2023
<div>Abstract<p>The DNA damage response (DDR) involves a complex network of signaling events mediated by modular protein domains such as the BRCA1 C-terminal (BRCT) domain. Thus, proteins that interact with BRCT domains and are a part of the DDR constitute potential targets for sensitization to DNA-damaging chemotherapy agents. We performed
Alvaro N. Monteiro, Uwe Rix, Eric B. Haura, Jhanelle E. Gray, Stephen G. Brantley, John M. Koomen, W. Douglas Cress, Elizabeth Remily-Wood, Jodi L. Kroeger, Fumi Kinose, Lily Rix, Gabriela Wright, Nicholas T. Woods, Ankita Jhuraney   +13 more
openaire   +1 more source

Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair

International Journal of Cancer, Volume 156, Issue 2, Page 417-430, 15 January 2025.
What's new? Drugs that act by inducing tumor cell death via DNA damage typically are effective only in the context of deficiencies in DNA repair mechanisms. Here, the authors investigated the relevance of DNA repair on the activity of Ascentawits (AST)‐3424, a novel prodrug activated by the tumor‐specific enzyme AKR1C3.
Fanying Meng, Tianyang Qi, Xing Liu, Yizhi Wang, Jibing Yu, Zhaoqiang Lu, Xiaohong Cai, Anrong Li, Don Jung, Jianxin Duan   +9 more
wiley   +1 more source

Supplementary Video S3 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

, 2017
Live cell imaging of histone-H2B-RFP expressing PCI13-G245D cells treated with vorinostat and AZD1775 combination.
Faye Johnson (11483644), Abdullah A. Osman (14920271), Curtis R. Pickering (13115535), Jeffrey N. Myers (222748), Noriaki Tanaka (8478), Nene N. Kalu (14933612), Tseng-Cheng Chen (558642), Mitchell J. Frederick (14871290), Antje Lindemann (15008477), Walter N. Hittelman (1274439), Siqing Fu (160695), Marek Kimmel (39636), Frederico O. Gleber-Netto (13907530), Ameeta A. Patel (14921678), Hideaki Takahashi (1269621), Jing Wang (6206297), Xiayu Rao (790781), Natalie L. Silver (14997050), Roman Jaksik (6309656), Jiping Wang (1319202), Lin Tang (65412)   +20 more
core   +1 more source

Targeting the DNA damage response in cancer

MedComm, Volume 5, Issue 11, November 2024.
DNA damage response pathway can be effectively targeted with different small molecules inhibitors. They can be used in tumors with specific genetic defects (synthetic lethal approach), in combination with chemotherapy and radiotherapy, in combination with immune checkpoints and in the resistant setting. Abstract DNA damage response (DDR) pathway is the
Federica Guffanti, Michela Chiappa, Giovanna Damia   +2 more
wiley   +1 more source

Suppl. Figures 1-5, Suppl. Table 1 from PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors

, 2018
Supplemental Figure 1: Cytotoxicity by combined WEE1 and PARP inhibition. Supplemental Figure 2: The effects of AZD1775 and olaparib on the radiation-induced G2 checkpoint.
Zachery R. Reichert (15078543), Mark J. O'Connor (14875842), Jonathan Vélez-Padilla (15078540), Jonathan Maybaum (1910515), Leslie A. Parsels (9291352), David Karnak (14986820), Theodore S. Lawrence (9291361), Meredith A. Morgan (9291364), Joshua D. Parsels (9291355), Qiang Zhang (45005), Daniel R. Wahl (14928302)   +10 more
core   +1 more source

Bromodomain and extraterminal domain inhibition synergizes with WEE1‐inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer [PDF]

, 2020
Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC). Previous studies have addressed the effect of BET-inhibiting drugs on the expression of oncogenes such
Jun Sakakibara‐Konishi, Motofumi Suzuki, Maeda, Makie, Hirotoshi Dosaka‐Akita, Tetsuaki Shoji, Furuta, Megumi, Kinoshita, Ichiro, Konno, Satoshi, Hajime Kikuchi, Satoshi Konno, Shoji, Tetsuaki, Eiki Kikuchi, Kikuchi, Eiki, Kikuchi, Hajime, Megumi Furuta, Makie Maeda, Yuta Takashima, Kikuchi, Junko, Junko Kikuchi, Dosaka-Akita, Hirotoshi, Suzuki, Motofumi, Sakakibara-Konishi, Jun, Ichiro Kinoshita, Takashima, Yuta   +23 more
core   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression

International Journal of Cancer, Volume 155, Issue 1, Page 104-116, 1 July 2024.
What's new? Biomarkers for better stratification of patients with ovarian cancer into existing targeted therapy scenarios and clinical trials are still missing. In this analysis of somatic and germline genetic variability using a custom panel of 144 high‐grade serous ovarian carcinoma‐related genes, gene expression of highly somatically mutated TP53 ...
Petr Holý, Viktor Hlaváč, Karolína Šeborová, Simona Šůsová, Tereza Tesařová, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah, Jiří Špaček, Iva Sedláková, Pavel Souček, Radka Václavíková   +15 more
wiley   +1 more source

Chemoradiotherapy and nanomedicine: Drug mechanisms and delivery systems

WIREs Nanomedicine and Nanobiotechnology, Volume 16, Issue 4, July/August 2024.
Chemoradiotherapy is a critical component of cancer treatment. This review will summarize key radiosensitizing drugs as well as nanomedicine methods to improve their delivery. Abstract Radiotherapy is an invaluable tool in the treatment of cancer. However, when used as a monotherapy, it fails to provide curative outcomes.
Matthew Molinaro, David Skrodzki, Dipanjan Pan   +2 more
wiley   +1 more source